GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » Total Inventories

Supernus Pharmaceuticals (Supernus Pharmaceuticals) Total Inventories : $77.4 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals Total Inventories?

Supernus Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $77.4 Mil. Supernus Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $80.4 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Supernus Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.83.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Supernus Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 374.00.

Inventory Turnover measures how fast the company turns over its inventory within a year. Supernus Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.24.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Supernus Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.49.


Supernus Pharmaceuticals Total Inventories Historical Data

The historical data trend for Supernus Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Total Inventories Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.63 48.33 85.96 91.54 77.41

Supernus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.54 91.15 90.56 83.48 77.41

Supernus Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Supernus Pharmaceuticals  (NAS:SUPN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Supernus Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(254.874+0.75 * 144.155+0.5 * 77.408-356.157
-0-0)/54.7234
=0.83

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Supernus Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=80.444/19.627*365 / 4
=374.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Supernus Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=19.627 / 80.444
=0.24

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Supernus Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=80.444 / 164.314
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Supernus Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (Supernus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Executives
Tami Tillotson Martin officer: Sr. V.P., Regulatory Affairs C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii director 1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson director 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Frank Mottola officer: Sr VP, Quality, GMP Oper. & IT 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Jack A. Khattar director, officer: President, CEO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt officer: Sr. VP of IP, CSO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Timothy C Dec officer: Senior Vice-President & CFO C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Jonathan Rubin officer: SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Schwabe Stefan K.f. officer: Executive Vice President R&D C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick officer: VP, Chief Financial Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly officer: Executive Vice-President & CFO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn officer: Sr. VP of Sales C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
M James Barrett director, 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202